Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT, TACE, and Lenvatinib in Advanced HCC
NCT05718232Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2023
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05718232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718232.